What does the evidence say about Urolithin A Exercise Performance Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Urolithin A Exercise Performance Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Individuals with sarcopenia face a significantly elevated risk of falls, fractures, cognitive impairment, and functional dependency, leading to increased hospitalization rates, prolonged lengths of stay, and greater healthcare costs [,,]. [Chin Hui San (2026); evidence level 4] - These disruptions converge on key processes such as reduced neuromuscular integrity, impaired energy metabolism, and blunted anabolic signaling, ultimately contributing to declines in muscle strength and function. [Chin Hui San (2026); evidence level 4] - As a narrative synthesis, formal systematic review methodology and risk-of-bias assessment, were not applied. [Chin Hui San (2026); evidence level 4] - 1 2 3 4 5 6 7 3 Sarcopenia, defined as the progressive loss of skeletal muscle mass and function, is widely acknowledged as a critical determinant of health outcomes in aging populations and patients with chronic disease. [Chin Hui San (2026); evidence level 4] - Proteomic screening of skeletal muscle biopsies revealed UA upregulated pathways associated with mitochondria, while downregulating inflammatory pathways. [Whitfield J (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.